0.5  0 (0%)		03-21 16:00
Open: 1.51 High: 1.51 Volume: 5,896,474		Pre. Close: 0.5 Low: 0.5 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.45	1-year :	0.59
Resists	First :	0.39	Second :	0.5
Pivot price	0.34
Supports	First :	0.2	Second :	0.16
MAs	MA(5) :	0.33	MA(20) :	0.35
	MA(100) :	3.7	MA(250) :	57.59
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	35.6	D(3) :	38.2
RSI	RSI(14): 39.7
52-week	High :	200	Low :	0.07

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TCBP ] has closed above bottom band by 27.3%. Bollinger Bands are 93% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 123 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.4 - 0.4	0.4 - 0.41
Low:	0.29 - 0.29	0.29 - 0.29
Close:	0.3 - 0.3	0.3 - 0.3

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Wed, 11 Jun 2025
Blood Cancer Breakthrough: Patient Achieves Complete Response After Just 2 Doses of Novel Cell Therapy - Stock Titan

Fri, 21 Mar 2025
TC BioPharm Faces Nasdaq Exit: What This OTC Markets Move Means for Investors - Stock Titan

Fri, 21 Mar 2025
TC BioPharm to be delisted from Nasdaq, moves to OTC Markets - Investing.com

Fri, 21 Mar 2025
TC BioPharm Transitions from Nasdaq to OTC Markets Amid Delisting Notice - TipRanks

Thu, 20 Feb 2025
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - PR Newswire

Wed, 05 Feb 2025
TC BioPharm's Major ADS Restructure: What This 1:20 Ratio Change Means For Your Holdings - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	1 (M)
Held by Insiders	9.887e+007 (%)
Held by Institutions	0 (%)
Shares Short	4 (K)
Shares Short P.Month	0 (K)

EPS	-4
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-98.2 %
Return on Equity (ttm)	-577.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.133e+009
Qtrly Earnings Growth	794.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.08
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	49370
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.